[Angiogenesis inhibitors and radiation therapy: from biology to clinical practice].
Angiogenesis is central to cancer research. Recent progresses in understanding its mechanisms have enabled the development of therapies that inhibit this process. Many molecules have shown a synergistic effect in combination with irradiation in preclinical studies, and several are being tested in phase I or II. This effect could be explained by a transient normalization of tumor vasculature, leading to improve tumor oxygenation and thus greater radiosensitivity. Although promising, many questions remain about the dose, optimal sequences of the association.
Mazeron
R
R
Département de Radiothérapie, Institut Gustave-Roussy, 94805 Villejuif, France.
Azria
D
D
Deutsch
E
E
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000532:radiotherapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D011836:Radiation Tolerance / Q000187:drug effects / Q000502:physiology; D011878:Radiotherapy / Q000379:methods*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2